Cancer Immunology, Immunotherapy

, Volume 54, Issue 3, pp 208–218 | Cite as

Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma

  • Peter Hersey
  • Scott W. Menzies
  • Brendon Coventry
  • Tam Nguyen
  • Margaret Farrelly
  • Susan Collins
  • Debbie Hirst
  • Heather Johnson
Original Article


Previous studies in small groups of patients suggested that immunization of melanoma patients with peptide epitopes recognized by T cells could induce regression of melanoma. This approach was tested in 36 patients with stage IV melanoma. The (MHC class I–restricted) peptides were from gp100, MART-1, tyrosinase, and MAGE-3. The gp100 and MART-1 peptides had been modified to increase their immunogenicity. In half the patients (groups 3 and 4) the peptides were given in the adjuvant Montanide-ISA-720, and half the patients in both groups were given GM-CSF s.c. for 4 days following each injection. Treatment was well tolerated except for two severe erythematous responses to Montanide-ISA-720 and marked inflammatory responses at sites of GM-CSF administration in three patients. There were no objective clinical responses but stabilization of disease for periods from 3 to 12 months were seen in seven patients. Five of these were patients given the peptides in Montanide-ISA-720. Delayed-type hypersensitivity (DTH) skin test responses were also seen mainly in the patients given the peptides in Montanide-ISA-720. GM-CSF did not increase DTH responses in patients in the latter group but may have increased DTH responses in those not given peptides in Montanide-ISA-720. Inflammatory responses around s.c. metastases or regional lymph nodes were observed in two patients. These results suggest that the peptides are more effective when given in the adjuvant Montanide-ISA-720. Nevertheless, results from this study, together with those from a number of comparable studies, indicate that peptide vaccines are currently of minimal benefit to patients and support the need for ongoing development of new strategies in treatment of this disease.


Adjuvants Clinical responses Melanoma Peptide vaccines T-cell responses 



This work was supported by the National Health and Medical Research Council of Australia and in part by the Sydney Melanoma Foundation and the Hunter Melanoma Foundation.


  1. 1.
    Abdel-Wahab Z, Kalady MF, Emani S, Onaitis MW, Abdel-Wahab OI, Cisco R, Wheless L, Cheng TY, Tyler DS, Pruitt SK (2003) Induction of anti-melanoma CTL response using DC transfected with mutated mRNA encoding full-length Melan-A/MART-1 antigen with an A27L amino acid substitution. Cell Immunol 224:86CrossRefPubMedGoogle Scholar
  2. 2.
    Anderson CT, Roumiantzeff M, Kniker WT (1978) The multitest system for assay of delayed cutaneous hypersensitivity (DCH) to ubiquitous antigens. J Allergy Clin Immunol 61:167Google Scholar
  3. 3.
    Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V (2002) Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 1:111PubMedGoogle Scholar
  4. 4.
    Brichard V, van Pel A, Wolfel T, Wolfel C, De-Plaen E, Lethe B, Coulie P, Boon T (1993) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178:489CrossRefPubMedGoogle Scholar
  5. 5.
    Coventry BJ, Heinzel S (2004) CD1a in human cancers: a new role for an old molecule. Trends Immunol (in press)Google Scholar
  6. 6.
    Disis ML, Gralow JR, Bernhard H, Hand SL, Rubin WD, Cheever MA (1996) Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic self-protein. J Immunol 156:3151PubMedGoogle Scholar
  7. 7.
    Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber D, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Dura P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850CrossRefPubMedGoogle Scholar
  8. 8.
    Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F, Boon T (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. Immunogenetics 39:121PubMedGoogle Scholar
  9. 9.
    Hersey P, Coates AS, McCarthy WH, Thompson JF, Sillar RW, McLeod R, Gill G, Coventry BJ, Dillon H, Simes RJ (2002) Adjuvant immunotherapy of patients with high risk melanoma with vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 20:4181CrossRefPubMedGoogle Scholar
  10. 10.
    Hersey P, Menzies SW, Halliday GM, Nguyen T, Farrelly ML, DeSilva C, Lett M (2003) Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother 53:125CrossRefPubMedGoogle Scholar
  11. 11.
    Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B (1996) Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 56:2479PubMedGoogle Scholar
  12. 12.
    Jaeger E, Bernhard H, Romero P, Ringhoffer M, Arand M, Karback J, Ilsemann C, Hagedorn M, Knuth A (1996) Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 66:162CrossRefPubMedGoogle Scholar
  13. 13.
    Jaeger E, Ringhoffer M, Dienes HP, Arand M, Karbach J, Jager D (1996) Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 67:54CrossRefPubMedGoogle Scholar
  14. 14.
    Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Apella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA (1994) Identification of a melanoma antigen recognised by tumour infiltrating lymphocytes associated with in vivo tumour rejection. Proc Natl Acad Sci U S A 91:6458PubMedGoogle Scholar
  15. 15.
    Kennedy LJ, Poulton KV, Thomson W, Williams F, Middleton D, Howell WM, Tarassi K, Papasteriades C, Albert E, Fleischauer K, Chandanayingyong D, Tiercy JM, Juji T, Tokunago K, Ollier WER (1997) HLA class I DNA typing using sequence specific oligonucleotide probes (SSOP). In: Charron D (ed) Genetic diversity of HLA: functional and medical implication. Proceedings of the 12th International Histocompatibility Workshop, p 216Google Scholar
  16. 16.
    Lee KH, Wang E, Nielsen MB, Wunderlich J, Migueles S, Connors M, Steinberg SM, Rosenberg SA, Marincola FM (1999) Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 163:6292PubMedGoogle Scholar
  17. 17.
    Ma J, Urba WJ, Si L, Wang Y, Fox BA, Hu HM (2003) Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. Eur J Immunol 33:2123CrossRefPubMedGoogle Scholar
  18. 18.
    Mandic M, Almunia C, Vicel S, Gillet D, Janjic B, Coval K, Maillere B, Kirkwood JM, Zarour HM (2003) The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells. Cancer Res 63:6506PubMedGoogle Scholar
  19. 19.
    Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y (1995) Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 63:883PubMedGoogle Scholar
  20. 20.
    Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Lienard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jager E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T (1999) Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80:219CrossRefPubMedGoogle Scholar
  21. 21.
    Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U, Hakansson L, van Baren N, Humblet Y, Mulders P, Avril MF, Eggermont AM, Scheibenbogen C, Uiters J, Wanders J, Delire M, Boon T, Stoter G (2003) Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 39:70CrossRefPubMedGoogle Scholar
  22. 22.
    Mitchell MS, Darrah D, Stevenson L (2002) Therapy of melanoma with allogeneic melanoma lysates alone or with interferon-alfa. Cancer Invest 20:759CrossRefPubMedGoogle Scholar
  23. 23.
    Morton DL, Hsueh EC, Essner R, Foshag LJ, O’Day SJ, Bilchik A, Gupta RK, Hoon DS, Ravindranath M, Nizze JA, Gammon G, Wanek LA, Wang HJ, Elashoff RM (2002) Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 236:438CrossRefPubMedGoogle Scholar
  24. 24.
    Nijman HW, Houbiers JGA, Vierboom MPM, Van Der Burg SH, Drijfhout JW, D’Amaro J, Kenemans P, Melief CJM, Kast WM (1993) Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol 23:1215PubMedGoogle Scholar
  25. 25.
    Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA, Kawakami Y (1996) Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 157:2539PubMedGoogle Scholar
  26. 26.
    Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM, Anichini A (2002) Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 94:805CrossRefPubMedGoogle Scholar
  27. 27.
    Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100:8372CrossRefPubMedGoogle Scholar
  28. 28.
    Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321PubMedGoogle Scholar
  29. 29.
    Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Seipp CA, Einhorn JH, Roberts B, White DE (1998) Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 90:1894CrossRefPubMedGoogle Scholar
  30. 30.
    Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Sznol M, Schwarz SL, Spiess PJ, Wunderlich JR, Seipp CA, Einhorn JH, Rogers-Freezer L, White DE (1999) Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol 163:1690PubMedGoogle Scholar
  31. 31.
    Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE (2003) Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther 14:709CrossRefPubMedGoogle Scholar
  32. 32.
    Rubio V, Stuge TB, Singh N, Betts MR, Weber JS, Roederer M, Lee PP (2003) Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 9:1377CrossRefPubMedGoogle Scholar
  33. 33.
    Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA (1996) Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 56:4749PubMedGoogle Scholar
  34. 34.
    Scalzo AA, Elliott SL, Cox J, Gardner J, Moss DJ, Suhrbier A (1995) Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720). J Virol 69:1306PubMedGoogle Scholar
  35. 35.
    Schaed SG, Klimek VM, Panageas KS, Musselli CM, Butterworth L, Hwu W-J, Livingston PO, Williams L, Lewis JJ, Houghton AN, Chapman PB (2002) T-cell responses against tyrosinase 368-376 (370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund’s adjuvant, granulcotye macrophage colony-stimulaitng factor, and QS-21 as immunological adjuvants. Clin Cancer Res 8:967PubMedGoogle Scholar
  36. 36.
    Scheibenbogen C, Schmittel A, Keilholz U, Allgauer T, Hofmann U, Thiel E, Schadendorf D (1999) Vaccination with tyrosinase peptides and GM-CSF in metastatic melanoma: a phase II trial. In: Proceedings of ASCO 18, p 436aGoogle Scholar
  37. 37.
    Skipper JCA, Hendrickson RC, Gulden PH, Brichard V, van Pel A, Chen Y, Shabanowitz J, Wolfel T, Slingluff CL Jr, Boon T, Hunt DF, Engelhard VH (1996) An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 183:527CrossRefPubMedGoogle Scholar
  38. 38.
    Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, Neese PY, Grosh WW, Chianese-Bullock KA, Woodson EM, Wiernasz CJ, Merrill P, Gibson J, Ross M, Engelhard VH (2003) Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 21:4016CrossRefPubMedGoogle Scholar
  39. 39.
    Terando A, Mule JJ (2003) On combining antineoplastic drugs with tumor vaccines. Cancer Immunol Immunother 52:680CrossRefPubMedGoogle Scholar
  40. 40.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Nat Canc Inst 92:205CrossRefGoogle Scholar
  41. 41.
    Valmori D, Fonteneau J-F, Lizana CM, Gervois N, Lienard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini J-C, Romero P (1998) Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 160:1750PubMedGoogle Scholar
  42. 42.
    Valmori D, Gileadi U, Servis C, Dunbar PR, Cerottini JC, Romero P, Cerundolo V, Levy F (1999) Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J Exp Med 189:895CrossRefPubMedGoogle Scholar
  43. 43.
    Valmori D, Lienard D, Waanders G, Rimoldi D, Cerottini J-C, Romero P (1997) Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. Cancer Res 57:735PubMedGoogle Scholar
  44. 44.
    van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P, de Smet C, Traversari C, Townsend A, Boon T (1994) A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24:3038PubMedGoogle Scholar
  45. 45.
    Vierboom MPM, Nijman HW, Offringa R, Van Der Voort Eih, van Hall T, van den Broek L, Fleuren GJ, Kenemans P, Kast WM, Melief CJM (1997) Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 186:695CrossRefPubMedGoogle Scholar
  46. 46.
    Weber J, Sondak VK, Scotland R, Phillip R, Wang F, Rubio V, Lee PP, Groshen SG, Gee C, Jeffery GG, Sian S, Lee P (2003) Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected stage II melanoma. Cancer 97:186CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Peter Hersey
    • 1
  • Scott W. Menzies
    • 2
  • Brendon Coventry
    • 3
  • Tam Nguyen
    • 1
  • Margaret Farrelly
    • 1
  • Susan Collins
    • 4
  • Debbie Hirst
    • 2
  • Heather Johnson
    • 2
  1. 1.Oncology and Immunology UnitNewcastleAustralia
  2. 2.Sydney Melanoma UnitRoyal Prince Alfred HospitalCamperdownAustralia
  3. 3.Adelaide Melanoma Unit, Department of Surgery, Royal Adelaide HospitalUniversity of AdelaideAdelaideAustralia
  4. 4.Newcastle Melanoma UnitNewcastle Mater HospitalWaratahAustralia

Personalised recommendations